Virus-Based therapy takes on tough cancers in early trial
NCT ID NCT07190833
First seen Nov 01, 2025 · Last updated Jun 02, 2026 · Updated 25 times
Summary
This early-phase study tests a new drug called OTS-412, made from a modified virus, alone or with other drugs, in 27 adults with advanced solid tumors that stopped responding to standard care. The main goal is to check safety and side effects, while also looking at whether tumors shrink. The trial is currently recruiting participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT-REFRACTORY SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dong-A University Hospital
RECRUITINGBusan, 49201, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Pusan National University Yangsan Hospital
RECRUITINGBusan, 50612, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.